GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Y

Yubo International Biotech YBGJ · USD

N/A · US listing · 🇺🇸 United States

Compare

0.01

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$134,391

FY2016FY2025

Net income

−$1.1m

FY2016FY2025

Free cash flow

−$842,804

FY2016FY2025

Shareholders' equity

−$2.0m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$134,391$3,470$604,676$104,283$1.2m$1.4m————
Gross profit$8,165−$209,275$419,185$52,652$820,647$1.2m————
Operating income−$1.2m−$1.8m−$1.2m−$1.2m−$1.5m−$711,798−$29,000−$48,000−$58,000−$149,000
Net income−$1.1m−$1.8m−$1.2m−$1.2m−$1.5m−$711,804−$134,000−$148,000−$144,000−$224,000
Diluted earnings per share-0.01-0.01-0.01-0.01-0.01-0.01-0.11-0.13-0.04-0.00

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$847,094$1.5m$1.7m$2.3m$4.6m$2.4m$1,000$4,000$5,000$4,000
Cash and short-term investments$8,062$7,015—$18,220$27,517$1.4m—$4,000$2,000$1,000
Total liabilities$2.8m$4.8m$3.5m$2.9m$4.7m$1.3m$1.8m$1.7m$1.5m$1.4m
Debt$78,783$478,765—$790,499$2.7m$315,207—$1.3m$1.2m$935,000
Shareholders' equity−$2.0m−$3.4m−$1.8m−$565,373−$131,198$1.2m−$1.8m−$1.7m−$1.5m−$1.4m
Shares outstanding140m120m120m119m118m118m1m1m3m118m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$842,802−$1.3m−$738,971$68,233−$1.0m$101,107−$682,121−$32,000−$55,000−$55,000
Capital spending−$2——−$39,772−$564,718−$97,468−$36,983———
Free cash flow−$842,804−$1.3m−$738,971$28,461−$1.6m$3,639−$719,104−$32,000−$55,000−$55,000

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue——$134,391———−$18—
Gross profit−$28,771−$31,516$141,519−$43,587−$45,144−$44,623−$13—
Operating income−$238,861−$289,274−$315,800−$310,134−$249,699−$467,299−$357,298−$532,764
Net income−$247,949−$272,608−$136,514−$276,771−$230,333−$435,630−$289,654−$580,843
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Total assets$672,272$709,872$847,094$953,211$1.1m$1.2m$1.5m$1.7m
Cash and short-term investments$11,989$10,382$8,062$10,926$10,416$9,773$7,015—
Debt$15,655$1.5m$78,783$138,604$177,131$200,343$367,992—
Shareholders' equity−$2.6m−$2.3m−$2.0m−$1.7m−$4.0m−$3.7m−$3.4m−$3.1m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue8.8%-37.0%—
Operating income-0.5%10.8%34.1%
Net income-3.6%8.7%23.6%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin-145.9%32.0%67.7%—
Operating margin-2145.4%-632.7%-221.0%—
Net margin-2070.6%-620.5%-217.9%—

Valuation history

At each fiscal year end

FY2025FY2024
Price to earnings-0.1-0.0
Price to sales0.52.7

Share price return

Finished calendar years

20252024202320222021
Return389%1338%2412%532%141%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 100-to-1 reverse split · 5 Mar 2007

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.